Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06945614 · ClinicalTrials.gov registry record · Phase 1
Exploratory Clinical Study to Assess Safety and Efficacy of Xenon Gas Inhalation to Control Neuroinflammation
A Phase 1 study of Healthy Volunteer Study, sponsored by General Biophysics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT06945614: Recruiting Phase 1 study of Healthy Volunteer Study, sponsored by General Biophysics.
NCT06945614 is a Phase 1 study of Healthy Volunteer Study that is actively recruiting participants, run by General Biophysics. The registered enrollment target is 16 participants, below the 35-participant average among 9 other Healthy Volunteer Study trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06945614, a Phase 1 study of Healthy Volunteer Study, is actively recruiting participants, sponsored by General Biophysics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical study is to evaluate safety of Xenon gas inhalation in healthy volunteers. This first phase safety clinical study is part of evaluation of the xenon gas inhalation as a therapy for neurodegenerative diseases, such as Alzheimer's disease. The investigators will administer xenon gas in low concentration to people via anesthetic machine, observe participants for sedation and any unexpected side effects, collect blood at each visit and measure the vital signs. There are four treatment groups in the study, which correspond with the duration of xenon gas treatment. Individual participation will last approximately 14 days over five visits: screening visit accompanied by the electrocardiogram, blood, and urine test; treatment visit for xenon gas inhalation treatment; and three follow up visits.
Primary Outcome
To determine the safety of xenon gas inhalation for 10, 20, 30, and 45 minutes in healthy volunteers. Investigators anticipate to observe no sedation, no nausea, and no vomiting. Measured Parameters for Safety Assessments during Xenon Administration (Intraoperative - every five (5) minutes): * Heart rate * Blood pressure * Respiratory rate * Body temperature * Peripheral blood oxygenation * Changes in capnometry * Electrocardiographic parameters and printed rhythm strip * Adverse events Depth
Conditions Studied
Interventions
- DRUG Xenon gas inhalation
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2025-04-16 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 1 |
What NCT06945614 shows while recruiting
NCT06945614 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 35-participant average among 9 other Healthy Volunteer Study trials with a reported enrollment target (54% lower).
The record links to 1 condition, with Healthy Volunteer Study appearing as the primary indexed condition, and to 1 intervention - of which Xenon gas inhalation is the first listed.
NCT06945614 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06945614 about?
NCT06945614 is a clinical study titled "Exploratory Clinical Study to Assess Safety and Efficacy of Xenon Gas Inhalation to Control Neuroinflammation". The goal of this clinical study is to evaluate safety of Xenon gas inhalation in healthy volunteers. This first phase safety clinical study is part of evaluation of the xenon gas inhalation as a therapy for neurodegenerative diseases, such as Alzheimer's disease. The investigators will administer x...
What is the current status of trial NCT06945614?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2025-04-16. Estimated completion is 2025-12-31.
What conditions does trial NCT06945614 study?
This clinical trial studies the following conditions: Healthy Volunteer Study.
What interventions are being tested in trial NCT06945614?
The interventions under investigation include: Xenon gas inhalation (DRUG).
Who is sponsoring clinical trial NCT06945614?
This trial is sponsored by General Biophysics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06945614 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Volunteer Study
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06945614's enrollment target sits among peer trials
16 8th of 9 higher than 2 of 9 other Healthy Volunteer Study trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Volunteer Study trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
RECRUITING · Phase 1
-
A Pharmacokinetic Study of Intravenous and Intranasal Oxytocin in Healthy Subjects
COMPLETED · Phase 1
-
A Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of ALG-055009 Formulations
COMPLETED · Phase 1
-
Study of Intranasal Octreotide (DP1038) in Healthy Adult Volunteers
COMPLETED · Phase 1
-
Mass Balance Study of AT-527 in Healthy Adult Male Subjects (R07496998)
COMPLETED · Phase 1
-
Near-InfraRed Spectroscopy of Auricular Stimulation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI